Applied and Computational Mathematics and Statistics

Search CurateND

Search criteria:

Department or Unit: Applied and Computational Mathematics and Statistics remove × Type of Work: Book OR Patent remove ×
Clear all

List of files deposited in CurateND that match your search criteria

  • Author(s):
    Daniel Bates, Charles Wampler, Andrew Sommese, Jonathan Hauenstein
    Abstract:

    This book is a guide to concepts and practice in numerical algebraic geometry—the solution of systems of polynomial equations by numerical methods. Through numerous examples, the authors show how to apply the well-received and widely used open-source Bertini software package to compute solutions, including a detailed manual on syntax and usage options. The authors also maintain a complementary web page where readers can find supplementary materials and Bertini input files.

    Date Created:
    2016-02-23
    Resource Type
    Book
  • Inventor(s):
    Steven Buechler, Amanda B. Hummon
    Patent Number:
    US 9580756 B2
    Description:

    Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4…

    Date Issued:
    2017-02-28
    Resource Type
    Patent
  • Inventor(s):
    Steven Buechler, Amanda B. Hummon
    Patent Number:
    US 9464328 B2
    Description:

    Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression v…

    Date Issued:
    2016-10-11
    Resource Type
    Patent
  • Inventor(s):
    Steven Buechler
    Patent Number:
    US 9721067 B2
    Description:

    An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MKI67, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified…

    Date Issued:
    2017-08-01
    Resource Type
    Patent
  • Inventor(s):
    Steven Buechler, Amanda B. Hummon
    Patent Number:
    US 10,087,489 B2
    Description:

    Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression v…

    Date Issued:
    2018-10-02
    Resource Type
    Patent
  • Inventor(s):
    Sunil Badve, Steven Buechler, Yesim Gokmen-Polar
    Patent Number:
    US 10174382 B2
    Description:

    A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may…

    Date Issued:
    2019-01-08
    Resource Type
    Patent